Since amplified expression of Tyro3 was observed in sorafenib-resistant HCC cells, it was also proposed that combining miR-7 with the inhibition of Tyro3 might represent a new therapeutic strategy to overcome sorafenib resistance. Here, TYRO3 is linked to hepatocellular carcinoma.